The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain
This work aimed to analyze the value of serum platelet/lymphocyte ratio (PLR), carbohydrate antigen 125 (CA125), and diffusion-weighted imaging (DWI) in the diagnosis of recurrent ovarian cancer. Forty-three patients with suspected recurrence of ovarian cancer were deemed as research objects, and 5 healthy people were set as controls. PLR, DWI, and CA125 level before surgery were analyzed. Pearson correlation analysis was implemented to explore the correlation between CA125 and lymphocyte count, platelet count, and PLR. Neuropathic Pain Scale was adopted to analyze the analgesic effect of patients with recurrent ovarian cancer before treatment and 7 days after treatment. Moreover, the quality of life scores of patients with recurrent ovarian cancer were evaluated before treatment and 30 days after treatment. The platelet and PLR values of patients with recurrent ovarian cancer were significantly higher relative to healthy people (P < 0.001), while the lymphocyte count was relatively lower (P = 0.002). There were considerable differences in PLR and CA125 levels in patients with recurrent ovarian cancer before and after treatment (P < 0.001). The single detection of CA125 was significantly better than that of DWI and PLR (P = 0.034). The sensitivity and specificity of CA125 detection alone was 77.3% and 81.8%, respectively, while those of the joint detection of DWI + PLR + CA125 was 92.4% and 79.9%, respectively. PLR was proved to be positively correlated with CA125 before and after treatment (r = 0.687, P < 0.001). Pain scores in all aspects of patients with recurrence of ovarian cancer after treatment were lower than that before treatment (P < 0.001), and the quality of life score was significantly higher than that before treatment (P < 0.001). CA125 and PLR combined with DWI had the best diagnostic effect for patients with recurrent ovarian cancer. After treatment, the levels of PLR and CA125 were reduced and the quality of life of patients was improved.